Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
Results from the phase 3 VERIFY trial showed that rusfertide significantly improved hematocrit control, reduced therapeutic phlebotomy requirements, and improved patient-reported symptom burden in patients with phlebotomy-dependent...
Results from the phase 3 VERIFY trial showed that rusfertide significantly improved hematocrit control, reduced therapeutic phlebotomy requirements, and improved patient-reported symptom burden in patients with phlebotomy-dependent...
Results from the phase 3 evERA Breast Cancer trial demonstrated significantly improved progression-free survival with giredestrant plus everolimus compared with standard endocrine therapy plus everolimus in previously treated patients with...
Results from the phase 3 evERA Breast Cancer trial demonstrated significantly improved progression-free survival with giredestrant plus everolimus compared with standard endocrine therapy plus everolimus in previously treated patients with...
Results from the phase 3 GIMEMA ALL2820 trial showed that frontline ponatinib plus blinatumomab significantly improved event-free survival and molecular response compared with imatinib plus chemotherapy in adult patients with newly diagnosed...
Results from the phase 3 GIMEMA ALL2820 trial showed that frontline ponatinib plus blinatumomab significantly improved event-free survival and molecular response compared with imatinib plus chemotherapy in adult patients with newly diagnosed...
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...